Picotamide是一种血小板聚集抑制剂，IC50值为0.76µM。
Cas No.:32828-81-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Picotamide is a platelet aggregation inhibitor with an IC50 value of 0.76μM[1]. Picotamide can inhibit the thromboxane A2 (TxA2) receptor and TxA2 synthase, prevent platelet aggregation, and regulate the inflammatory process of atherosclerotic plaques[2]. Picotamide has been widely used as a model compound to develop a series of derivatives for inhibiting platelet aggregation[3].
In vitro, Picotamide treatment at 300μM for 45 minutes inhibited the contraction of hyperplastic human prostate smooth muscle induced by adrenergic and thromboxane[4]. Treatment with 300μM Picotamide for 45 minutes inhibited in the smooth muscle contractions induced by the phenylephrine, U46619, and electric field stimulation (EFS) in the lower urinary tract tissues[5]. Treatment with 300μM Picotamide for 30 minutes inhibited the smooth muscle contraction of the interlobular arteries in porcine renal interloba induced by phenylephrine [6].
In vivo, Picotamide treatment via intraperitoneal injection at a single dose of 375mg/kg 1 hour before thrombotic challenge could protect mice from death caused by intravenous injection of collagen plus epinephrine, and reduced the decline in circulating platelet count and pulmonary thromboembolism[7].
References:
[1] Liu X J, Shi X X, Zhong Y L, et al. Design, synthesis and in vitro activities on anti-platelet aggregation of 4-methoxybenzene-1, 3-isophthalamides[J]. Bioorganic & medicinal chemistry letters, 2012, 22(21): 6591-6595.
[2] Celestini A, Violi F. A review of picotamide in the reduction of cardiovascular events in diabetic patients[J]. Vascular Health and Risk Management, 2007, 3(1): 93-98.
[3] Zou J, Gao P, Hao X, et al. Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives[J]. European Journal of Medicinal Chemistry, 2018, 147: 150-162.
[4] Hennenberg M, Miljak M, Herrmann D, et al. The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle[J]. American Journal of Physiology-Renal Physiology, 2013, 305(10): F1383-F1390.
[5] Hennenberg M, Tamalunas A, Wang Y, et al. Inhibition of agonist-induced smooth muscle contraction by picotamide in the male human lower urinary tract outflow region[J]. European journal of pharmacology, 2017, 803: 39-47.
[6] Li B, Huang R, Wang R, et al. Picotamide inhibits a wide spectrum of agonist‐induced smooth muscle contractions in porcine renal interlobar and coronary arteries[J]. Pharmacology Research & Perspectives, 2021, 9(3): e00771.
[7] Gresele P, Corona C, Alberti P, et al. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression[J]. Thrombosis and haemostasis, 1990, 64(05): 080-086.
Picotamide是一种血小板聚集抑制剂，IC50值为0.76µM[1]。Picotamide可抑制血栓素A2（TxA2）受体和TxA2合酶，防止血小板聚集，并调节动脉粥样硬化斑块的炎症过程[2]。Picotamide已被广泛用作模型化合物，以开发一系列用于抑制血小板聚集的衍生物 [3]。
在体外，使用300µM的Picotamide处理45分钟，抑制了肾上腺素能和血栓素诱导的增生性人前列腺平滑肌收缩[4]。使用300µM的Picotamide处理45分钟，抑制了下尿路组织中由phenylephrine、U46619和电场刺激（EFS）诱导的平滑肌收缩[5]。使用300µM的Picotamide处理30分钟，抑制了phenylephrine诱导的猪肾叶间动脉的平滑肌收缩[6]。
在体内，血栓形成激发前1小时单次腹腔注射Picotamide（375mg/kg），可保护小鼠免于因静脉注射胶原蛋白加肾上腺素引起的死亡，并减轻了循环血小板计数的下降和肺血栓栓塞[7]。
| Animal experiment [1]: | |
Animal models | Male Swiss CD1 mice |
Preparation Method | Male Swiss CD1 mice, weighing 20-25g, were caged and fed a regular diet for at least 1 week before use. Picotamide or vehicle was administered by intraperitoneal (i. p.) route, in a dose of 375mg/kg. One hour after the i. p. pretreatment of Picotamide, 100μl of a mixture of collagen (250μg/ml) and epinephrine (15μg/ml) in 0.154M NaCl was injected rapidly (in less than 2min) into a tail vein. Mouse blood anticoagulated with trisodium citrate 3.8% was collected by heart puncture under ether anesthesia and centrifuged for analysis. |
Dosage form | 375mg/kg for once; i.p. |
Applications | Picotamide treatment significantly reduced the drop in the number of circulating platelets in the blood of mice with pulmonary embolism. |
References: | |
| Cas No. | 32828-81-2 | SDF | |
| 别名 | 吡考胺 | ||
| 化学名 | 4-methoxy-N1,N3-bis(3-pyridinylmethyl)-1,3-benzenedicarboxamide | ||
| Canonical SMILES | O=C(C1=CC=C(OC)C(C(NCC2=CC=CN=C2)=O)=C1)NCC3=CN=CC=C3 | ||
| 分子式 | C21H20N4O3 | 分子量 | 376.4 |
| 溶解度 | 1mg/mL in ethanol, 5mg/ml in DMSO, 10mg/mL in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6567 mL | 13.2837 mL | 26.5675 mL |
| 5 mM | 531.3 μL | 2.6567 mL | 5.3135 mL |
| 10 mM | 265.7 μL | 1.3284 mL | 2.6567 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet